Design and synthesis of tenofovir monophenyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.110401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Xiaolei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China; Jiangsu Hanso…. Hauptthemen laut MEDLINE: Prodrugs, Tenofovir, Hepatitis B virus, Antiviral Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Tenofovir Alafenamide (TAF, formerly known as GS-7340, Fig. 1-C) is a prodrug of Tenofovir (TFV) that contains a phosphonoamidate group. Compared to Tenofovir Disoproxil Fumarate (TDF), TAF exhibits enhanced stability in non-target tissues, promoting selective accumulation of Tenofovir (TFV) in target cells (e.g., PBMCs and hepatocytes). Subsequent phosphorylation convert TFV to its active form, Tenofovir Diphosphate (TFV-DP), thereby potentiating therapeutic efficacy. However, detectable levels of TFV in whole blood following TAF administration underscore potential safety risks, highlighting the need for novel TFV prodrugs with improved whole-blood stability. However, detectable levels of TFV in whole blood following TAF administration underscore potential safety risks, highlighting the need for novel TFV prodrugs with enhanced whole-blood stability and therapeutic efficacy. In this study, a series of TFV phosphonoamidate prodrugs incorporating disubstituted amino acids were designed and synthesized. Compared with TAF, compound 3a1 exhibited exceptional stability, with no detectable metabolite-TFV found in human whole blood. Furthermore, PBMC-based TFV quantification was employed as a clinically relevant measure of intracellular prodrug delivery and metabolic activation, consistent with the FDA's evaluation framework for tenofovir alafenamide in HBV-infected patients. Under this framework, compound 3a1 demonstrated significantly enhanced intracellular TFV accumulation in PBMCs compared with TAF. Collectively, these results position 3a1 as a promising next-generation TFV prodrug with potential for improved efficacy and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China; Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Jiangsu 222047, China.
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd, Jiangsu 222047, China.
- School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China. Electronic address: wusonggu@tju.edu.cn.
- School of Chemical Engineering and Technology, State Key Laboratory of Chemical Engineering, Tianjin University, Tianjin 300072, China. Electronic address: junbo_gong@tju.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, X., Li, S., Xu, N., Sun, Y., Liu, D., Yu, J., Wu, S., & Gong, J. (2026). Design and synthesis of tenofovir monophenyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.110401
Vancouver
Wang X, Li S, Xu N, Sun Y, Liu D, Yu J, et al. Design and synthesis of tenofovir monophenyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.110401
BibTeX
@article{Wang2026,
author = {Wang, Xiaolei and Li, Sai and Xu, Ning and Sun, Yundong and Liu, Delong and Yu, Jun and Wu, Songgu and Gong, Junbo},
title = {Design and synthesis of tenofovir monophenyl ester phosphonoamidate prodrugs with improved anti-hepatitis B virus activity and intrahepatic tenofovir enrichment},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.110401}
}
EUVIMED